Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

The pandemic COVID-19 has spread widely throughout the globe and has been responsible
for millions of deaths worldwide. Recently, it has been identified that there is no specific and …

Background: While passive immunotherapy has been considered beneficial for patients with
severe respiratory viral infections, the treatment of COVID-19 cases with convalescent …

Background Plasma collected from recovered COVID-19 patients (COVID-19 convalescent
plasma, CCP) was the first antibody-based therapy employed to fight the COVID-19 …

Background Studies on the antiviral effects of remdesivir have shown conflicting results.
SARS-CoV-2 viraemia could identify patients in whom antiviral treatment may be particularly …

Background There is a need to understand the relationship between COVID-19
Convalescent Plasma (CCP) anti-SARS-CoV-2 IgG levels and clinical outcomes to optimize …

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), emerged in 2019 following prior outbreaks of coronaviruses like SARS and …

Background: Sample size estimation is an essential step in the design of randomized
controlled trials (RCTs) evaluating a treatment effect. Sample size is a critical variable in …

The aim of this review was to update evidence for benefit of convalescent plasma
transfusion (CPT) in patients with coronavirus disease 2019 (COVID-19). Databases were …

Convalescent plasma therapy might be a feasible option for treatment of novel infections.
During the early phases of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV …